Secondary outcome: Inflammatory response (overall Inflammation score) for all participants Mean grade of inflammation in each group² · participants with melanoma in situ, including lentigo maligna
1 finding from 1 review
PASI‐75 (number of participants with event) · people with chronic plaque psoriasis
Salt bath + UVB may leads to higher PASI‐75 (number of participants with event) compared with UVB alone (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · people with chronic plaque psoriasis
Salt bath + UVB showed no clear difference in treatment‐related adverse events requiring withdrawal (number of… compared with UVB alone (low certainty).
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Participant satisfaction · people with eczema
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
It is very uncertain whether topical active treatment in combination with moisturiser changes number of participants reporting an adverse event compared with topical active treatment alone (very low certainty).
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Topical active treatment in combination with moisturiser may leads to lower number of participants who experienced a flare compared with topical active treatment alone (low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Flutamide 250 mg once to b.i.d. showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with spironolactone 100 mg (low certainty).
1 finding from 1 review
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Spironolactone 100 mg showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants who reported an adverse event · women with hirsutism
Spironolactone 100 mg showed no clear difference in proportion of participants who reported an adverse event compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
1 finding from 1 review
Proportion of participants who reported an adverse event · patients with hirsutism
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg showed no clear difference in proportion of participants who reported an adverse event compared with ethinyl estradiol 30 μg + desogestrel 0.15 mg (moderate certainty).
1 finding from 1 review
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether finasteride 5 mg to 7.5 mg changes proportion of participants who reported an adverse event compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
1 finding from 1 review
Proportion of participants who reported an adverse event · women with hirsutism
Finasteride 5 mg showed no clear difference in proportion of participants who reported an adverse event compared with spironolactone 100 mg (moderate certainty).
1 finding from 1 review